Biodexa Pharmaceuticals (BDRX) Total Debt (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Total Debt across 13 years of filings, most recently posting $81140.1 for Q4 2025.

• In Q4 2025, Total Debt fell 91.3% year-over-year to $81140.1; the TTM figure through Dec 2025 stood at $81140.1 (down 91.3% YoY), while the FY2025 annual figure was $80429.1, down 91.35% from the prior year.
• Total Debt came in at $81140.1 for Q4 2025 at Biodexa Pharmaceuticals, down from $668356.9 in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.1 million in Q2 2021 to a low of $81140.1 in Q4 2025.
• Average Total Debt over 5 years is $721873.7, with a median of $706324.4 recorded in 2022.
• Year-over-year, Total Debt surged 200.76% in 2021 and sank 91.3% in 2025.
• Over 5 years, Total Debt stood at $1.0 million in 2021, then dropped by 29.12% to $731907.3 in 2022, then decreased by 21.32% to $575894.5 in 2023, then surged by 62.03% to $933105.8 in 2024, then sank by 91.3% to $81140.1 in 2025.
• Per Business Quant data, the three most recent Total Debt figures were $81140.1 in Q4 2025, $668356.9 in Q2 2025, and $933105.8 in Q4 2024.